胰岛素样生长因子信号轴与其抑制剂在肿瘤中的作用

田静; 付瑶; 孙钰; 王志浩

doi:10.16152/j.cnki.xdxbzr.2024-05-010

您当前的位置：

首页 >

文章列表页 >

胰岛素样生长因子信号轴与其抑制剂在肿瘤中的作用

西北大学生物学科办学100周年专刊 | 更新时间：2024-09-30

- 胰岛素样生长因子信号轴与其抑制剂在肿瘤中的作用
- The roles of Insulin-like growth factor signaling axis and its inhibitors in tumors
- 西北大学学报（自然科学版） 2024年54卷第5期页码：876-888
- 作者机构：
  
  西北大学　生命科学学院/西部资源生物与现代生物技术教育部重点实验室，陕西　西安　710069
- 作者简介：
  
  田静，女，教授，博士生导师，从事分子遗传与发育研究，tianjing@nwu.edu.cn。
- 基金信息：
  
  国家自然科学基金面上项目(32170618)
- DOI：10.16152/j.cnki.xdxbzr.2024-05-010
  中图分类号： Q71
- 纸质出版日期：2024-10-25，
  
  收稿日期：2024-07-28，
- 稿件说明：
移动端阅览
田静, 付瑶, 孙钰, 等. 胰岛素样生长因子信号轴与其抑制剂在肿瘤中的作用[J]. 西北大学学报（自然科学版）, 2024,54(5):876-888.

TIAN Jing, FU Yao, SUN Yu, et al. The roles of Insulin-like growth factor signaling axis and its inhibitors in tumors[J]. Journal of Northwest University (Natural Science Edition), 2024,54(5):876-888.
田静, 付瑶, 孙钰, 等. 胰岛素样生长因子信号轴与其抑制剂在肿瘤中的作用[J]. 西北大学学报（自然科学版）, 2024,54(5):876-888. DOI： 10.16152/j.cnki.xdxbzr.2024-05-010.

TIAN Jing, FU Yao, SUN Yu, et al. The roles of Insulin-like growth factor signaling axis and its inhibitors in tumors[J]. Journal of Northwest University (Natural Science Edition), 2024,54(5):876-888. DOI： 10.16152/j.cnki.xdxbzr.2024-05-010.

摘要

胰岛素样生长因子（IGFs）是一种体内平衡调节因子，参与全身多种生理、合成和代谢过程，在促进生长中起着关键的自分泌、旁分泌和内分泌作用，涉及多种组织器官内细胞增殖、分化和凋亡的调节。大量体内、体外实验及临床报道发现IGFs分子的异常表达在各种呼吸系统、消化道恶性肿瘤、生殖系统肿瘤及其他肿瘤的增殖侵袭过程中都起到十分重要的作用。从临床角度来看，异常表达的IGF信号轴分子可被认定为癌症的诊断标志物、预后因素和现代抗肿瘤治疗的靶点。因此，针对不同肿瘤组织中IGFs变化所引发的下游分子及信号通路改变，配合靶向分子抑制剂进行针对性用药，可能成为治疗癌症的新方式。总结了IGFs信号轴在正常人体与癌症组织发展中的变化，并对IGFs信号轴的小分子抑制剂进行归纳，希望能为以后的癌症临床治疗与研究提供借鉴，为未来分子靶向治疗辅助癌症用药提供一定的参考。

Abstract

Insulin-like growth factors (IGFs) are homeostasis regulatory factors that participate in diverse physiological

synthetic and metabolic processes throughout the body and play key autocrine

paracrine and endocrine roles in promoting growth

involving the regulation of cell proliferation

differentiation and apoptosis in various tissues and organs. Numerousin

vivo

and

in vitro

experiments and clinical reports have found that the abnormal expression of IGF molecules plays a crucial role in the proliferation and invasion of various organ cancers

reproductive system cancers and other tumors. From a clinical perspective

IGF signaling axis can be recognized as potential biomarkers in diagnosis

prognosis

and therapy for cancer. Therefore

targeting the downstream molecular and signaling pathway changes caused by IGFs in different cancer tissues

combined with targeted molecular inhibitors for targeted drug use

may become a new way to treat cancer. Here

we summarize the changes of IGFs signaling in different tumor tissues

and include the small molecule inhibitors of IGFs axis. This review aims to provide guidance for future clinical treatment and research of cancer to a certain extent

and to provide some reference for the use of molecular targeted therapy as an adjunct to cancer dr

ugs in the future.

关键词

胰岛素样生长因子肿瘤抑制剂靶点治疗

Keywords

IGFstumorsinhibitorstarget therapy

references

BAKER L D, BARSNESS S M, BORSON S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: Results of a controlledtrial[J]. Archives of Neurology, 2012, 69(11): 1420-1429.

TREJO J L, PIRIZ J, LLORENS-MARTIN M V, et al. Central actions of liver-derived insulin-like growth factor I underlying its pro-cognitive effects[J]. Molecular Psychiatry, 2007, 12(12): 1118-1128.

HOLLY J M P, PERKS C M. Insulin-like growth factor physiology: What we have learned from humanstudies[J]. Endocrinology and Metabolism Clinics of North America, 2012, 41(2): 249-263.

KAPLAN S A, COHEN P. REVIEW: The somatomedin hypothesis 2007: 50 years later[J]. The Journal of Clinical Endocrinology & Metabolism, 2007, 92(12): 4529-4535.

DEIJEN J B, ARWERT L I, DRENT M L. The GH/IGF-I axis and cognitive changes across a 4-year period in healthy adults[J]. ISRN Endocrinology, 2011, 2011(1): 249421.

BOWERS L W, ROSSI E L, O’FLANAGAN C H, et al. The role of the insulin/IGF system in cancer: Lessons learned from clinical trials and the energy balance-cancer link[J]. Frontiers in Endocrinology, 2015, 6: 77.

SAMANI A A, YAKAR S, LEROITH D, et al. The role of the IGF system in cancer growth and metastasis: Overview and recent insights[J]. Endocrine Reviews, 2007, 28(1): 20-47.

OSHER E, MACAULAY V M. Therapeutic targeting of the IGF axis[J]. Cells, 2019, 8(8): 895.

UNGER C, KRAMER N, UNTERLEUTHNER D, et al. Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms[J]. Oncogene, 2017, 36(38): 5341-5355.

YU H, ROHAN T. Role of the insulin-like growth factor family in cancer development and progression[J]. JNCI: Journal of the National Cancer Institute, 2000, 92(18): 1472-1489.

TOGNON C E, SORENSEN P H B. Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy[J]. Expert OpiniononTherapeutic Targets, 2012, 16(1): 33-48.

KASPRZAK A, ADAMEK A. The insulin-like growth factor (IGF) signaling axis and hepatitis C virus-associated carcinogenesis (review)[J]. International Journal of Oncology, 2012, 41(6): 1919-1931.

FIRTH S M, BAXTER R C. Cellular actions of the insulin-like growth factor binding proteins[J]. Endocrine Reviews, 2002, 23(6): 824-854.

QUAN H Y, TANG H, FANG L, et al. IGF1(CA)19 and IGFBP-3-202A/C gene polymorphism and cancer risk: A meta-analysis[J]. Cell Biochemistry and Biophysics, 2014, 69(1): 169-178.

VIGNERI P G, TIRRÒ E, PENNISI M S, et al. The insulin/IGF system in colorectal cancer development and resistance to therapy[J]. Frontiers in Oncology, 2015, 5: 230.

FU S L, TANG H X, LIAO Y D, et al. Association of preoperative serum IGF-I concentration with clinicopathological parameters in patients with non-small cell lung cancer[J]. Journal of Huazhong University of Science and Technology(Medical Sciences), 2013, 33(2): 224-227.

KNACKE H, PIETZNER M, DO K T, et al. Metabolic fingerprints of circulating IGF-1 and the IGF-1/IGFBP-3 ratio: A multifluid metabolomics study[J]. The Journal of Clinical Endocrinology and Metabolism, 2016, 101(12): 4730-4742.

CAO H X, WANG G H, MENG L, et al. Association between circulating levels of IGF-1 and IGFBP-3 and lung cancer risk: A meta-analysis[J]. PLoS One, 2012, 7(11): e49884.

POHLMAN A W, MOUDGALYA H, JORDANO L, et al. The role of IGF-pathway biomarkers in determining risks, screening, and prognosis in lung cancer[J]. Oncotarget, 2022, 13: 393-407.

TAKANAMI I, IMAMUMA T, HASHIZUME T, et al. Insulin-like growth factor-II as a prognostic factor in pulmonary adenocarcinoma[J]. Journal of Surgical Oncology, 1996, 61(3): 205-208.

KIM J S, KIM E S, LIU D E, et al. Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer[J]. Clinical Lung Cancer, 2014, 15(3): 213-221.

KIM J S, KIM E S, LIU D E, et al. Activation of insulin-like growth factor 1 receptor in patients with non-small-cell lung cancer[J]. Oncotarget, 2015, 6(18): 16746-16756.

KARMALI R, LARSON M L, SHAMMO J M, et al. Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia[J]. Leukemia & Lymphoma, 2015, 56(11): 3135-3142.

XU G J, CHU J S, SHI Y, et al. The regulation of proliferation and apoptosis in hepatocellular carcinoma via insulin-like growth factor 1 receptor[J]. Growth Hormone & IGF Research, 2022, 66: 101499.

YAN X D, YAO M, WANG L, et al. Overexpression of insulin-like growth factor-I receptor as a pertinent biomarker for hepatocytes malignant transformation[J]. World Journal of Gastroenterology, 2013, 19(36): 6084-6092.

HUANG X P, ZHOU W H, ZHANG Y F. Genetic variations in the IGF-IGFR-IGFBP axis confer susceptibility to lung and esophageal cancer[J]. Genetics and Molecular Research, 2014, 13(1): 2107-2119.

KUNH H, FRILLE A, PETERSE M A, et al. IGFBP3 inhibits tumor growth and invasion of lung cancer cells and is associated with improved survival in lung cancer patients[J]. Translational Oncology, 2023, 27: 101566.

LIU P, SUN Y H, LIU S, et al. SY-707, an ALK/FAK/IGF1R inhibitor, suppresses growth and metastasis of breast cancer cells[J]. Acta Biochimica et Biophysica Sinica, 2022, 54(2): 252-260.

NUR S, OZTURK A, KAVAS M, et al. IGFBP-4: A promising biomarker for lung cancer[J]. Journal of Medical Biochemistry, 2021, 40(3): 237-244.

YAO R S, WANG Y A, LUBET R A, et al. Differentially expressed genes associated with mouse lung tumor progression[J]. Oncogene, 2002, 21(37): 5814-5821.

GUO B L, LV Z, CUI C G, et al. IGF-1R transported to the cell nuclei to regulate the proliferation of breast cancer cells[J]. Cell Biochemistry and Biophysics, 2021, 79(4): 801-813.

BAHHNASSY A, MOHANAD M, SHAARAWY S, et al. Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: Prognostic and predictive markers in triple-negative and non-triple-negative breast cancer[J]. Molecular Medicine Reports, 2015, 12(1): 851-864.

HARTOG H, BOEZEN H M, DE JONG M M, et al. Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer[J]. The Breast, 2013, 22(6): 1155-1160.

HAMILTON N, MÁRQUEZ-GARBÁN D, MAH V, et al. Biologic roles of estrogen receptor-β and insulin-like growth factor-2 in triple-negative breast cancer[J]. BioMed Research International, 2015, 2015(1): 925703.

KHADKA V S, NASU M, DENG Y P, et al. Circulating microRNA biomarker for detecting breast cancer in high-risk benign breast tumors[J]. International Journal of Molecular Sciences, 2023, 24(8): 7553.

KALLEDS∅E L, DRAGSTED L O, HANSEN L, et al. The insulin-like growth factor family and breast cancer prognosis: A prospective cohort study among postmenopausal women in Denmark[J]. Growth Hormone & IGF Research: Official Journal of the Growth Hormone Research Society and the International IGF Research Society, 2019, 44: 33-42.

RICHARDSONA E, HAMILTON N, DAVIS W, et al. Insulin-like growth factor-2(IGF-2) activates estrogen receptor-α and-β via the IGF-1 and the insulin receptors in breast cancer cells[J]. Growth Factors, 2011, 29(2/3): 82-93.

SUN W Y, YUN H Y, SONG Y J, et al. Insulin-like growth factor 1 receptor expression in breast cancer tissue and mammographic density [J]. Molecular and Clinical Oncology, 2015, 3(3): 572-580.

SHIN S J, GONG G, LEE H J, et al. Positive expression of insulin-like growth factor-1 receptor is associated with a positive hormone receptor status and a favorable prognosis in breast cancer[J]. Journal of Breast Cancer, 2014, 17(2): 113-120.

OBR A, KUMAR S, BIRGE R, et al. Abstract 3617: A paradigm shift for insulin-like growth factor 1 receptor function in triple negative breast cancers[J]. Cancer Research, 2017, 77(13): 3617.

DE GROOT S, CHAREHBILI A, VAN LAARHOVEN H W M, et al. Insulin-like growth factor 1 receptor expression and IGF1R 3129G> T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: Results from the NEOZOTAC trial (BOOG 2010-01)[J]. Breast Cancer Research: BCR, 2016, 18(1): 3.

YAN J, YANG X, LI L, et al. Low expression levels of insulin-like growth factor binding protein-3 are correlated with poor prognosis for patients with hepatocellular carcinoma[J]. Oncology Letters, 2017, 13(5): 3395-3402.

BACH L A. IGF-binding proteins[J]. Journal of Molecular Endocrinology, 2018, 61(1): T11-T28.

HOEFLICH A, RUSSO V C. Physiology and pathophysiology of IGFBP-1 and IGFBP-2-consensus and dissent on metabolic control and malignant potential[J]. Best Practice & Research Clinical Endocrinology & Metabolism, 2015, 29(5): 685-700.

CONWAY J R W, DINÇ D D, FOLLAIN G, et al. IGFBP2 secretion by mammary adipocytes limits breast cancer invasion[J]. Science Advances, 2023, 9(28): e1840.

HORNE H N, SHERMAN M E, PFEIFFER R M, et al. Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: A cross-sectional study of women with benign breast disease[J]. Breast Cancer Research: BCR, 2016, 18(1): 24.

ARAFAT H M, OMAR J, SHAFII N, et al. The association between the serum level of IGF-1 and IGFBP-3 and the risk of breast cancer among women in the gaza strip[J]. Asian Pac J Cancer Prev, 2023, 24(2): 717-723.

DITTMER J. Biological effects and regulation of IGFBP5 in breast cancer[J]. Frontiers in Endocrinology, 2022, 13: 983793.

WANG W Y, LIM K G, FENG M, et al. KDM6B counteracts EZH2-mediated suppression of IGFBP5 to confer resistance to PI3K/AKT inhibitor treatment in breast cancer[J]. Molecular Cancer Therapeutics, 2018, 17(9): 1973-1983.

ROSENDAHL A H, BJÖRNER S, RÖDSTRÖM M Y, et al. Pre-and postoperative circulating IGF-I, IGFBP-3, and IGFBP-7 levels in relation to endocrine treatment and breast cancer recurrence: A nested case-control study[J]. Frontiers in Oncology, 2021, 11: 626058.

HIMOTO T, TANI J, MIYOSHI H, et al. The ratio of insulin-like growth factor-I/insulin-like growth factor-binding protein-3 in sera of patients with hepatitis C virus-related chronic liver disease as a predictive marker of insulin resistance[J]. Nutrition Research, 2013, 33(1): 27-33.

ESPELUND U, GR∅NBÆK H, VILLADSEN G E, et al. The circulating IGF system in hepatocellular carcinoma: The impact of liver status and treatment[J]. Growth Hormone & IGF Research, 2015, 25(4): 174-181.

LIU S, LIU Y H, JIANG X W. Prognostic significance of serum insulin-like growth factor-1 in patients with hepatocellular carcinoma following transarterial chemoembolization[J]. Experimental and Therapeutic Medicine, 2016, 11(2): 607-612.

LACIN S, YALCIN S, KARAKAS Y, et al. Prognostic significance of serum insulin-like growth factor-1 in hepatocellular cancer patients: A validation study[J]. Journal of Hepatocellular Carcinoma, 2020, 7: 143-153.

VILLANUEVA A, PORTELA A, SAYOLS S, et al. DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma[J]. Hepatology, 2015, 61(6): 1945-1956.

WHITTAKER S, MARAIS R, ZHU A X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma[J]. Oncogene, 2010, 29(36): 4989-5005.

COUVERT P, CARRIÉ A, DU MONTCEL S T, et al. Insulin-like growth factor 2 gene methylation in peripheral blood mononuclear cells of patients with hepatitis C related cirrhosis or hepatocellular carcinoma[J]. Clinics and Research in Hepatology and Gastroenterology, 2012, 36(4): 345-351.

QIAN J, YAO D F, DONG Z Z, et al. Characteristics of hepatic IGF-II expression and monitored levels of circulating IGF-II mRNA in metastasis of hepatocellular carcinoma[J]. American Journal of Clinical Pathology, 2010, 134(5): 799-806.

TAI B J, YAO M, ZHENG W J, et al. Alteration of oncogenic IGF-II gene methylation status associates with hepatocyte malignant transformation[J]. Hepatobiliary&Pancreatic Diseases International: HBPD INT, 2019, 18(2): 158-163.

DAI B, RUAN B, WU J, et al. Insulin-like growth factor binding protein-1 inhibits cancer cell invasion and is associated with poor prognosis in hepatocellular carcinoma[J]. International Journal of Clinical and Experimental Pathology, 2014, 7(9): 5645-5654.

YAN J J, YANG X Z, LI L, et al. Low expression levels of insulin-like growth factor binding protein-3 are correlated with poor prognosis for patients with hepatocellular carcinoma[J]. Oncology Letters, 2017, 13(5): 3395-3402.

REGEL I, EICHENMÜLLER M, JOPPIEN S, et al. IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically silenced in vascular invasive and metastatic tumors[J]. Molecular Cancer, 2012, 11: 9.

OLGA PEMÍA, ROSAS R, JULIA JIMÉNEZ, et al. Determination of IGFBP-3 methylation levels at ctDNA could be a prognostic biomarker in advanced stages of NSCLC[J]. IBJ Plus, May 2018, DOI: 10.24217/2531-0151.18v1s2.00041http://doi.org/10.24217/2531-0151.18v1s2.00041.

BROWN K M, XUE A Q, SMITH R C, et al. Cancer-associated stroma reveals prognostic biomarkers and novel insights into the tumour microenvironment of colorectal cancer and colorectal liver metastases[J]. Cancer Medicine, 2022, 11(2): 492-506.

CHEN D, YOO B K, SANTHEKADUR P K, et al. Insulin-like growth factor-binding protein-7 functions as a potential tumor suppressor in hepatocellular carcinoma[J]. Clinical Cancer Research, 2011, 17(21): 6693-6701.

BIE C Q, CHEN Y F, TANG H J, et al. Insulin-like growth factor 1 receptor drives hepatocellular carcinoma growth and invasion by activating Stat3-midkine-Stat3 loop[J]. Digestive Diseases and Sciences, 2022, 67(2): 569-584.

DACOSTA S A, SCHUMAKER L M, ELLIS M J. Mannose 6-phosphate/insulin-like growth factor 2 receptor, a bona fide tumor suppressor gene or just a promising candidate？[J]. Journal of Mammary Gland Biology and Neoplasia, 2000, 5(1): 85-94.

LAUTEM A, SIMON F, HOPPE-LOTICHIUS M, et al. Expression and prognostic significance of insulin-like growth factor-2 receptor in human hepatocellular carcinoma and the influence of transarterial chemoembolization[J]. Oncology Reports, 2019, 41(4): 2299-2310.

KNUPPEL A, FENSOM G K, WATTS E L, et al. Circulating insulin-like growth factor-I concentrations and risk of 30 cancers: Prospective analyses in UK biobank[J]. Cancer Research, 2020, 80(18): 4014-4021.

PETERS G, GONGOLL S, LANGNER C, et al. IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer[J]. Virchows Archiv: An International Journal of Pathology, 2003, 443(2): 139-145.

王志明, 蒲九君, 孙彦龙, 等. IGF-1和IGF-1R在无功能性垂体腺瘤中的表达及意义[J]. 第三军医大学学报, 2015, 37(13): 1367-1372.

WANG Z M, PU J J, SUN Y L, et al. Expression of insulin-like growth factor 1 and its receptor inhuman non-functioning pituitary adenomas: Correlation with invasiveness and recurrence[J]. Journal of Army Medical University, 2015, 37(13): 1367-1372.

WU X Y, WU Z F, CAO Q H, et al. Insulin-like growth factor receptor-1 overexpression is associated with poor response of rectal cancers to radiotherapy[J]. World Journal of Gastroenterology, 2014, 20(43): 16268-16274.

KUMAR A A-O, SINGH P A-O, PANDEY A A-O, et al. IGFBP3 gene promoter methylation analysis and its association with clinicopathological characteristics of colorectal carcinoma[J]. Molecular Biology Reports, 2020, 47(9): 6919-6927.

KING E R, ZU Z F, TSANG Y T M, et al. The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma[J]. Gynecologic Oncology, 2011, 123(1): 13-18.

LEE S W, LEE S Y, LEE S R, et al. Plasma levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in women with cervical neoplasia[J]. Journal of Gynecologic Oncology, 2010, 21(3): 174-180.

张瑞敏, 芦晓, 晏妮. 宫颈癌患者血清胰岛素样生长因子1、基质金属蛋白酶9的水平及临床意义[J]. 癌症进展, 2019, 17(18): 2204-2206, 2226.

ZHANG R M, LU X, YAN N. Serum levels of insulin-like growth factor 1 and matrix metalloproteinase 9 in patients with cervical cancer and their clinical significance[J]. Oncology Progress, 2019, 17(18): 2204-2206, 2226.

LI Y S, LIU Q, HE H B, et al. The possible role of insulin-like growth factor-1 in osteosarcoma[J]. Current Problems in Cancer, 2019, 43(3): 228-235.

LIU S, LIU Y, JIANG X. Prognostic significance of serum insulin like growth factor 1 in patients with hepatcellular carcinoma following transarterial chemoembolization[J]. Experimental and Therapeutic Medicine, 2016, 11(2): 607-612.

张丽娜, 闫华, 关宏, 等. IGF-2、IGF-1R、IGF-2R在子宫内膜腺癌的表达及临床意义[J]. 中国妇幼保健, 2010, 25(29): 4284-4287.

ZHANG L N, YAN H, GUAN H, et al. Expressions of IGF-2, IGF-1R and IGF-2R in endometrial adenocarcinoma and clinical significance[J]. Maternal and Child Health Care of China, 2010, 25(29): 4284-4287.

WATTS E L, PEREZ-CORNAGO A, FENSOM G K, et al. Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: A collaborative analysis of 20 prospective studies and Mendelian randomization analysis[J]. International Journal of Epidemiology, 2023, 52(1): 71-86.

SHARMA M, SATYAM A, ABHISHEK A, et al. Molecular and circulatory expression of insulin growth factors in Indian females with advanced cervical cancer[J]. Asian Pac J Cancer P, 2012, 13(12): 6475-6479.

LODHIA K A, TIENCHAIANANDA P, HALUSKA P. Understanding the key to targeting the IGF axis in cancer: A biomarker assessment[J]. Frontiers in Oncology, 2015, 5: 142.

LIU Y J, QIANG W, SHI J, et al. Expression and significance of IGF-1 and IGF-1R in thyroid nodules[J]. Endocrine, 2013, 44(1): 158-164.

FUHRER D, ESZLINGER M, KARGER S, et al. Evaluation of insulin-like growth factor II, cyclooxygenase-2, ets-1 and thyroid-specific thyroglobulin mRNA expression in benign and malignant thyroid tumours[J]. European Journal of Endocrinology, 2005, 152(5): 785-790.

CAI Q, DOZMOROV M, OH Y. IGFBP-3/IGFBP-3 receptor system as an anti-tumor and anti-metastatic signaling in cancer[J]. Cells, 2020, 9(5): 1261.

SCHEDLICH L J, YENSON V M, BAXTER R C. TGF-β-induced expression of IGFBP-3 regulates IGF1R signaling in human osteosarcoma cells[J]. Molecular and Cellular Endocrinology, 2013, 377(1/2): 56-64.

LUTHER G A, LAMPLOT J, CHEN X, et al. IGFBP5 domains exert distinct inhibitory effects on the tumorigenicity and metastasis of human osteosarcoma[J]. Cancer Letters, 2013, 336(1): 222-230.

DE SOUZA R R, OLIVEIRA I D, DEL GIUDICE PANIAGO M, et al. Investigation of IGF2, Hedgehog and fusion gene expression profiles in pediatric sarcomas[J]. Growth Hormone & IGF Research, 2014, 24(4): 130-136.

HUANG H J, ANGELO L S, RODON J, et al. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing’s sarcoma: Convergence at the IGF/IGFR/Akt axis[J]. PLoS One, 2011, 6(10): e26060.

GENUA M, XU S Q, BURASCHI S, et al. Proline-rich tyrosine kinase 2 (Pyk2) regulates IGF-I-induced cell motility and invasion of urothelial carcinoma cells[J]. PLoS One, 2012, 7(6): e40148.

TSAI C W, CHANG W S, XU Y F, et al. Associations of genetically predicted circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 with bladder cancer risk[J]. Molecular Carcinogenesis, 2021, 60(11): 726-733.

VERHAGEN H J, DE LEEUW D C, ROEMER M G, et al. IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival[J]. Cell Death & Disease, 2019, 5(6): e1300.

CHEN X L, ZHENG J K, ZOU Y Z, et al. IGF binding protein 2 is a cell-autonomous factor supporting survival and migration of acute leukemia cells[J]. Journal of Hematology & Oncology, 2013, 6(1): 72.

KÜHNL A, KAISER M, NEUMANN M, et al. High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia[J]. Leukemia Research, 2011, 35(12): 1585-1590.

IOANNOU N, SEDDON A M, DALGLEISH A, et al. Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells[J]. BMC Cancer, 2013, 13: 41.

ZHOU H, RAO J, LIN J, et al. The insulin-like growth factor-I receptor kinase inhibitor NVP-ADW742 sensitizes medulloblastoma to the effects of chemotherapy[J]. Oncology Reports, 2011, 25(6): 1565-1571.

SCHULTZE A, DECKER S, OTTEN J, et al. TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis[J]. Investigational New Drugs, 2009, 28(6): 825-833.

NISHIO M, MURAKAMI H, HORIIKE A, et al. Phase I study of ceritinib (LDK378) in Japanese patients with advanced, anaplastic lymphoma kinase-rearranged non-small-cell lung cancer or other tumors[J]. Journal of Thoracic Oncology, 2015, 10(7): 1058-1066.

YOUSSF C, CUBILLOS-ROJAS M, COMALADA M, et al. Myeloid p38α signaling promotes intestinal IGF-1 production and inflammation-associated tumorigenesis[J]. EMBO Molecular Medicine, 2018, 10(7): e8403.

LIU P, SUN Y H, LIU S, et al. SY-707, an ALK/FAK/IGF1R inhibitor, suppresses growth and metastasis of breast cancer cells[J]. Acta BiochimicaetBiophysica Sinica, 2022, 54(2): 252-260.

FEI H D, YUAN Q, MAO L, et al. Assessment of GSK1904529A as a promising anti-osteosarcoma agent[J]. Oncotarget, 2017, 8(30): 49646-49654.

ZHOU F Y, CHEN X G, FAN S, et al. GSK1838705A, an insulin-like growth factor-1 receptor/insulin receptor inhibitor, induces apoptosis and reduces viability of docetaxel-resistant prostate cancer cells both in vitro and in vivo[J]. Onco Targets and Therapy, 2015, 8: 753-760.

WEI Y H, TANG H X, LIAO Y D, et al. Effects of insulin-like growth factor 1 receptor and its inhibitor AG1024 on the progress of lung cancer[J]. Journal of Huazhong University of Science and Technology(Medical Sciences), 2015, 35(6): 834-841.

PUZANOV I, LINDSAY C R, GOFF L, et al. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors[J]. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 2015, 21(4): 701-711.

FRANKS S E, JONES R A, BRIAH R, et al. BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549[J]. BMC Research Notes, 2016, 9(1): 134.

ZHANG C, ZHAO X N, WANG Z F, et al. Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase[J]. Investigational New Drugs, 2023, 41(3): 438-452.

JIN Y, GONG S, SHANG G C, et al. Profiling of a novel circadian clock-related prognostic signature and its role in immune function and response to molecular targeted therapy in pancreatic cancer[J]. Aging, 2023, 15(1): 119-133.

KONG Y L, SHEN Y, NI J, et al. Insulin deficiency induces rat renal mesangial cell dysfunction via activation of IGF-1/IGF-1R pathway[J]. Acta Pharmacologica Sinica, 2016, 37(2): 217-227.

MAHE M, DUFOUR F, NEYRET-KAHN H, et al. An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers[J]. EMBO Molecular Medicine, 2018, 10(4): e8163.

SUN X, LIANG J, YAO X, et al. The activation of EGFR promotes myocardial tumor necrosis factor-α production and cardiac failure in endotoxemia[J]. Oncotarget, 2015, 6(34): 35478-35495.

MANCARELLA C, MORRIONE A, SCOTLANDI K. Novel regulators of the IGF system in cancer[J]. Biomolecules, 2021, 11(2): 273.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据